— Know what they know.
Not Investment Advice

GBIO NASDAQ

Generation Bio Co.
1W: +3.8% 1M: +12.5% 3M: -5.8% 1Y: -46.9% 3Y: -86.5% 5Y: -98.4%
$5.34
Last traded 2025-12-31 — delisted
NASDAQ · Healthcare · Biotechnology · $36.0M mcap · 4M float · 1.96% daily turnover · Short 37% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$36.0M
52W Range3.004-7.516
Volume551,924
Avg Volume82,006
Beta2.01
Dividend
Analyst Ratings
5 Buy 5 Hold 0 Sell
Consensus Buy
Company Info
CEOYalonda Howze
Employees115
SectorHealthcare
IndustryBiotechnology
IPO Date2020-06-12
301 Binney Street
Cambridge, MA 02142
US
617 655 7500
About Generation Bio Co.

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
Atlas Venture Fund X U-Tender 60 $0.00 2026-02-09
Stehman-Breen Cather D-Return 6,000 $33.20 2026-02-09
Stehman-Breen Cather D-Return 3,000 $3.87 2026-02-09
Stehman-Breen Cather D-Return 5,200 $190.00 2026-02-09
Stehman-Breen Cather D-Return 1,500 $265.90 2026-02-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms